Home > Press > L’Institut de Biologie et Chimie des Proteines to Deploy E-WorkBook Suite to Accelerate Analysis of Nanoparticles
Abstract:
L'Institut de Biologie et Chimie des Proteines (IBCP) will be using E-WorkBook Suite to manage its research data and knowledge in developing nanoparticles for the treatment of viral infections. IBCP, a principal research institute based in Lyon, France, expects that E-WorkBook Suite will advance their research into creating vaccines using nanoparticles, which can emulate the actions of antigens and create a new generation of targeted therapeutics.
By using all aspects of E-WorkBook, scientists at IBCP can benefit from a flexible framework to capture, analyze and manage their experimental data in an efficient and compliant way. The solution's extensive searching and reporting capabilities will accelerate their pace of research, and maximize the quality and reuse of their data.
IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that L'Institut de Biologie et Chimie des Proteines (IBCP), a principal research institute based in Lyon, France, has selected E-WorkBook Suite to manage its research data and knowledge in developing nanoparticles for the treatment of viral infections.
Partnering with leading French and EU research organizations and universities, IBCP is advancing research into the creation of vaccines using nanoparticles made of polylactic acid (PLA), in sizes ranging from 150nm to 400nm, which can emulate the actions of antigens and create a new generation of targeted therapeutics. The biological application of nanoparticles is an area of nanotechnology that is rapidly developing, and it raises new possibilities in the diagnosis and treatment of HIV, Anthrax and FIV (Feline Immunodeficiency Virus).
By using all aspects of E-WorkBook, scientists at IBCP can benefit from a flexible framework to capture, analyze, and manage their experimental data in an efficient and compliant way. The solution's extensive searching and reporting capabilities will accelerate their pace of research, and maximize the quality and re-use of their data. IBCP is provided with an application that will streamline workflow, accelerate discovery research, and improve productivity, while ensuring quality control for standard operating procedures (SOPs) and protecting Intellectual Property (IP).
"I was impressed with the quality of results E-WorkBook produced for our colleagues from CEA (Fontenay-aux-Roses, France), and therefore it was the natural choice for our laboratory," said Professor Bernard Verrier, Senior Scientist at IBCP. "Using E-WorkBook we will have a clearer picture of the research going on in our lab, improving the quality and quantity of reports and scientific papers, and enabling better interpretation of results. Using this solution to manage our data will save us several months of work, preventing duplication of experiments and ensuring that new users to the system have a comprehensive view of all data."
"Nanotechnology is at the leading-edge of scientific research that has the potential to push technological boundaries," said Neil Kipling, founder and CEO of IDBS. "IBCP recognizes the power and flexibility of the E-WorkBook Suite and how it can be applied to further their pioneering work, which could represent a breakthrough in vaccinations for potentially fatal diseases. This relationship reaffirms IDBS' position at the forefront of scientific endeavor."
####
About IDBS
IDBS is a unique, global supplier of innovative data management and analytics solutions, which increase efficiency, reduce costs, and improve the business and scientific productivity of R&D organizations worldwide. Organizations such as Pfizer, GSK, Celera, MedImmune, Dana-Farber, and Roche employ IDBS solutions as an integral part of their strategy to address the increasing pressures placed upon them by the need for the secure and compliant capture, integration, and analysis of complex research data. IDBS is clearly differentiated from other software providers by its unique combination of deep domain knowledge and its ability to rapidly provide integrated business process and robust data analytics solutions along the entire R&D value chain. IDBS solutions secure organizations’ valuable R&D data assets and enable rapid decision-making through effective integration and analysis. They also support the protection of Intellectual Property (IP) and the requirements for data quality demanded under Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards.
IDBS is a private company, founded in 1989 and headquartered in Guildford, UK. IDBS has a worldwide consulting and support presence, with offices in California, New Jersey and Massachusetts in the US; and in the EU, Australia and China.
About IBCP
L’Institut de Biologie et Chimie des Proteines (IBCP), a 6000m² research unit (UMR 5086) administered jointly by the CNRS and by Lyon University, is located in Lyon (France). This "Protein Science" institute was created administratively in 1990 on the initiative of CNRS. The current director of IBCP is Prof. Gilbert Deléage. IBCP is an interdisciplinary research center focused on the "Molecular bases of infectious diseases" and "Cell and tissue dynamics". This center brings together 180 people distributed into 14 groups covering many scale approaches (atomic with NMR and crystallography, molecular studies with biochemistry techniques, cell biology cellular and tissular). Find out more at www.ibcp.fr
For more information, please click here
Contacts:
Kayley Edwards
Copyright © IDBS
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
New-Contracts/Sales/Customers
Bruker Light-Sheet Microscopes at Major Comprehensive Cancer Center: New Advanced Imaging Center Powered by Two MuVi and LCS SPIM Microscopes March 25th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Veeco Announces Aledia Order of 300mm MOCVD Equipment for microLED Displays: Propel™ Platform First 300mm System with EFEM Designed for Advanced Display Applications October 20th, 2020
GREENWAVES TECHNOLOGIES Announces Next Generation GAP9 Hearables Platform Using GLOBALFOUNDRIES 22FDX Solution October 16th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||